Smaller Is Often Better For Scientific Meetings, Researchers Report

Despite travel-budget cuts at many institutions and companies, as well as the growing number of gatherings on the annual calendar, attendance at many scientific meetings remains strong. But researchers are becoming choosier in deciding which conferences they will attend, more carefully weighing the expense--in both money and time spent away from the lab--against the expected scientific and career-building returns. Kenneth I. Berns, president-elect of the American Society for Microbiology (ASM),

Written byRicki Lewis
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

Despite travel-budget cuts at many institutions and companies, as well as the growing number of gatherings on the annual calendar, attendance at many scientific meetings remains strong. But researchers are becoming choosier in deciding which conferences they will attend, more carefully weighing the expense--in both money and time spent away from the lab--against the expected scientific and career-building returns.

Kenneth I. Berns, president-elect of the American Society for Microbiology (ASM), says of the organization's main meeting: "I'm amazed that attendance is so good." The gathering draws about 12,000, reports Berns, R.A. Rees Pritchett Professor and chairman of the department of microbiology at Cornell University Medical Center, New York City. "I've noticed that there are a lot more meetings, and people frequently go to the more specialized meetings that are more tailored to their interests, so that the general meetings may miss those people."

Specialized conferences are generally smaller, making it ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies